Phil Hodges began Metrics, Inc. in 1994 as a small contract analytical laboratory company with 4 employees. He oversaw its growth into a full-service pharmaceutical development and manufacturing organization serving clients worldwide. Metrics’ areas of expertise included quality pharmaceutical formulation development; first-time-in-man formulations; Phase I, II and III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial-scale manufacturing.
Metrics custom-built some 100,000 square feet of facility space, which includes a highly potent products containment suite that serves as a best-practices model for the entire industry and experienced double-digit revenue growth most years – and was profitable every year since 1995. Metrics grew its operations organically, adding new services as existing clients expressed interest and need. Throughout its growth, Metrics remained committed to scientific and operational excellence.
Metrics’ technical capabilities included highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence – for which it offered an impressive proprietary portfolio of advanced delivery methods. Over the years, Metrics conducted more than 130 first-time-in-man studies while producing 700-plus batches of clinical trial materials.
The company’s work supported investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.
In 2012, the company was acquired by Mayne Pharma Group Limited – a publicly traded pharmaceutical company based in Australia – that expanded the Metrics footprint into a truly global one. Besides being a large shareholder, Phil serves on the board of directors at Mayne Pharma.